GLP-3 RTA vs Ipamorelin
GLP-3 RTA and Ipamorelin come from different research areas and are studied in largely separate models — researchers usually compare them when scoping a broader protocol.
✓ both US-made · third-party tested · batch COA on every order
Last updated August 25, 2026
How do GLP-3 RTA and Ipamorelin differ?
GLP-3 RTA (Synthetic triple-agonist peptide) is catalogued under weight & metabolic research; Ipamorelin (Synthetic pentapeptide secretagogue) is catalogued under longevity & cellular research. Verve lists 5 reported research applications for GLP-3 RTA and 5 for Ipamorelin. Both are made in the United States, screened by HPLC to a 99%+ purity standard, and shipped with a batch-level certificate of analysis.
| field | GLP-3 RTA | Ipamorelin |
|---|---|---|
| compound class | Synthetic triple-agonist peptide | Synthetic pentapeptide secretagogue |
| research area | weight & metabolic | longevity & cellular |
| reported research applications | 5 listed | 5 listed |
| supplied as | single compound | single compound |
| catalog sizes | 10mg · 20mg · 30mg | 5mg · 10mg |
| purity standard | 99%+ by HPLC | 99%+ by HPLC |
| manufactured | United States | United States |
| batch COA | published per lot | published per lot |
| endotoxin-tested option | available | available |
| co-formulated together in | not co-formulated | not co-formulated |
| price from | $142.99 | $64.99 |
| availability | in stock | out of stock |
Prices and stock read live from the catalog. Both compounds are supplied strictly as reference materials for in-vitro laboratory research.
What is GLP-3 RTA and what is Ipamorelin?
GLP-3 RTA is classified as Synthetic triple-agonist peptide; Ipamorelin as Synthetic pentapeptide secretagogue. Both profiles below cover scientific identity only — what the molecule is and which laboratory models it appears in. Verve supplies both strictly as in-vitro reference materials, and neither profile describes human or veterinary use.
GLP-3 RTA
Synthetic triple-agonist peptide
GLP-3 RTA is a synthetic single-chain peptide engineered to act at three related class B G-protein-coupled receptors at once: the GLP-1 receptor, the GIP receptor, and the glucagon receptor. Its backbone is derived from the incretin peptide family and carries a fatty-acid modification that extends plasma half-life in pre-clinical systems, making it a widely cited reference agonist in incretin-receptor research.
full GLP-3 RTA profile →Ipamorelin
Synthetic pentapeptide secretagogue
Ipamorelin is a synthetic pentapeptide and a selective growth-hormone secretagogue, meaning it is characterized in the literature as an agonist at the growth-hormone secretagogue receptor (GHS-R1a), the same receptor targeted by the endogenous ligand ghrelin. Its selectivity profile is the reason it is so frequently chosen as a reference agonist in receptor-signaling work.
full Ipamorelin profile →Which research models is each compound studied in?
GLP-3 RTA sits in weight & metabolic research and Ipamorelin in longevity & cellular research, so their listed models largely do not intersect. The table lists 5 reported research applications for GLP-3 RTA and 5 for Ipamorelin. Rows are per compound, not equivalences.
| GLP-3 RTA — reported research applications | Ipamorelin — reported research applications |
|---|---|
| GLP-1, GIP, and glucagon receptor agonism research | GHS-R1a (ghrelin receptor) binding and agonist research |
| cAMP and class B GPCR signaling research models | Secretagogue-pathway signal-transduction research |
| Comparative single-, dual-, and triple-agonist pharmacology studies | Comparative receptor-selectivity studies against non-selective secretagogues |
| Metabolic-pathway and nutrient-handling research models | Endocrine-signaling research models |
| Peptide half-life, lipidation, and stability research | Peptide stability and structure–activity research |
Research contexts only. Both compounds are supplied for laboratory research use only, and no entry above describes an effect in humans or animals.
What sizes and prices does verve list for GLP-3 RTA and Ipamorelin?
GLP-3 RTA is listed from $142.99 and Ipamorelin from $64.99. The table below is every catalog size verve currently lists for the two compounds, at single-vial prices before the automatic multi-compound discount. Sizes describe the vial format supplied to the laboratory, nothing more.
| compound | size listed | price | availability |
|---|---|---|---|
| GLP-3 RTA | 10mg | $142.99 | in stock |
| GLP-3 RTA | 20mg | $242.99 | in stock |
| GLP-3 RTA | 30mg | $328.99 | in stock |
| Ipamorelin | 5mg | $64.99 | out of stock |
| Ipamorelin | 10mg | $114.49 | out of stock |
Any 2 different compounds take 20% off, any 3 take 30% — applied automatically in the cart, no code. Orders placed Monday–Friday ship by 2pm CT, free over $100.
shop the compounds →Frequently asked questions about GLP-3 RTA and Ipamorelin
What is GLP-3 RTA?
GLP-3 RTA is a synthetic peptide that acts as an agonist at three receptors — GLP-1, GIP, and glucagon. Verve supplies it as a research compound for laboratory use only, not for human or veterinary use.
What is GLP-3 RTA studied for in research?
In in-vitro and pre-clinical models it is used as a reference agonist in incretin-receptor pharmacology, cAMP signaling, and metabolic-pathway research. Verve makes no claims about use in humans or animals.
What is Ipamorelin?
Ipamorelin is a synthetic pentapeptide characterized as a selective agonist at the growth-hormone secretagogue receptor (GHS-R1a). Verve supplies it as a research compound for laboratory use only, not for human or veterinary use.
What is Ipamorelin studied for in research?
It is used as a reference agonist in GHS-R1a receptor-binding and secretagogue-pathway signaling research in in-vitro and pre-clinical models. Verve makes no claims about effects in humans or animals.
related comparisons
verve products are sold for laboratory research and development purposes only and are not intended for human or veterinary use of any kind. statements on this site have not been evaluated by the FDA.